Outpatient Pneumonia Antibiotic Treatment

Introduction to Treatment Guidelines

The American Thoracic Society recommends using amoxicillin 1 gram three times daily as first-line therapy for healthy adults without comorbidities, while combination therapy with amoxicillin-clavulanate plus azithromycin or respiratory fluoroquinolone monotherapy is recommended for patients with comorbidities 1, 2

For healthy adults without comorbidities, the first-line choice is amoxicillin 1 g three times daily for 5-7 days, with a strong recommendation and moderate quality evidence 1, 2
Alternative options for healthy adults without comorbidities include doxycycline 100 mg twice daily for 5-7 days, with a conditional recommendation and low quality evidence 1, 2
For adults with comorbidities, combination therapy with amoxicillin-clavulanate 875 mg/125 mg twice daily plus azithromycin 500 mg day 1, then 250 mg daily for 5-7 days total is preferred, with a strong recommendation and moderate quality evidence 1, 2

In areas with high macrolide resistance (≥25%), macrolide monotherapy should not be used, and combination therapy or fluoroquinolone should be used instead, as recommended by the American Thoracic Society 1, 2, 3
Patients with recent antibiotic exposure (within 90 days) should be treated with an agent from a different antibiotic class to reduce resistance risk, as recommended by the American Thoracic Society 2, 3

The standard duration of treatment is 5-7 days for most uncomplicated cases, as recommended by the American Thoracic Society 2, 3
Extended duration (14-21 days) is only recommended if Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli are identified, as recommended by the American Thoracic Society 2, 3

Amoxicillin is preferred for healthy adults because it provides excellent activity against Streptococcus pneumoniae, with 90-95% coverage of pneumococcal strains at high doses, as recommended by the American Thoracic Society 2
Combination therapy is mandatory for comorbid patients because it provides dual coverage against typical bacterial pathogens and atypical organisms, achieving 91.5% favorable clinical outcomes, as recommended by the American Thoracic Society 2

Macrolide monotherapy should not be used as first-line in any patient with comorbidities or in areas with ≥25% macrolide resistance, as recommended by the American Thoracic Society 1, 2, 3
Antibiotic duration should not be automatically extended beyond 5-7 days, and clinical improvement should be reassessed by day 2-3, as recommended by the American Thoracic Society 2